MedTrace Logo

Daratumumab After Stem Cell Transplant in Treating Patients With Multiple Myeloma

NCT03346135 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2025-12-05

No results posted yet for this study

Summary

This phase II trial studies how well daratumumab after a stem cell transplant works in treating patients with multiple myeloma. Monoclonal antibodies, such as daratumumab, may kill cancer cells that are left after chemotherapy.

Conditions

  • Plasma Cell Myeloma
  • Secondary Amyloidosis

Interventions

PROCEDURE

Autologous Hematopoietic Stem Cell Transplantation

Undergo standard of care ASCT with a conditioning regimen of melphalan

BIOLOGICAL

Daratumumab

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Melphalan

Undergo standard of care ASCT with a conditioning regimen of melphalan

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • City of Hope Medical Center

    lead OTHER

Principal Investigators

  • Amrita Y Krishnan · City of Hope Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-07-17
Primary Completion
2026-07-01
Completion
2026-07-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03346135 on ClinicalTrials.gov